Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Yasushi Shimizu"'
Autor:
Takayuki Yamada, Makoto Arai, Hitoshi Hirakawa, Naomi Kudo, Takashi Fujii, Kiyoaki Tsukahara, Akihiro Homma, Tomoya Yokota, Shin Kariya, Takeharu Ono, Moriyasu Yamauchi, Kenji Hanyu, Nobuya Monden, Nobuhiro Hanai, Ryuji Yasumatsu, Takahiro Asakage, Akihito Watanabe, Tsutomu Ueda, Shunji Takahashi, Koichi Omori, Takahiro Nekado, Yasushi Shimizu, Syuji Yonekura, Daisuke Sano, Tomoko Yamazaki, Mizuo Ando
Publikováno v:
International Journal of Clinical Oncology
Background We have previously reported the effectiveness and safety of nivolumab in patients with head and neck cancer (HNC) in real-world clinical practice in Japan. Here, we report long-term outcomes from this study in the overall population and su
Autor:
Hitoshi Hirakawa, Yasushi Shimizu, Moriyasu Yamauchi, Akihito Watanabe, Nobuhiro Hanai, Makoto Arai, Naomi Kudo, Ryuji Yasumatsu, Takeharu Ono, Shin Kariya, Masafumi Yoshida, Akinori Fujiwara, Takahiro Asakage, Kiyoaki Tsukahara, Shuji Yonekura, Takashi Fujii, Tomoko Yamazaki, Kenji Hanyu, Takayuki Yamada, Tomoya Yokota, Akihiro Homma, Daisuke Sano, Nobuya Monden, Tsutomu Ueda, Shunji Takahashi, Koichi Omori
Publikováno v:
International Journal of Clinical Oncology
Background To examine the effect of prior use of cetuximab and neck dissection on the effectiveness of nivolumab, we conducted a large-scale subgroup analysis in Japanese patients with recurrent/metastatic head and neck cancer. Methods Data on the ef
Autor:
Hirotoshi Dosaka-Akita, Naofumi Shinagawa, Masaki Kobayashi, Yoh Takekuma, Yasushi Shimizu, Mitsuru Sugawara, Ichiro Kinoshita, Ken Iseki, Yoshitaka Saito
Publikováno v:
European Journal of Clinical Pharmacology. 77:381-388
Purpose Gefitinib is one of the standard treatments for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor mutations. It has been reported that acid suppressants (AS) decrease the anti-tumor effect of gefitinib by reducing its s
Autor:
Takahisa Abe, Hirotoshi Dosaka-Akita, Takuro Noguchi, Yoshihito Ohhara, Tomohiro Goda, Jun Taguchi, Akihiro Homma, Satoshi Kano, Takatsugu Mizumachi, Yasushi Shimizu, Ichiro Kinoshita, Shin Ariga, Rio Honma, Toraji Amano, Miki Takahara, Satoshi Takeuchi
Publikováno v:
International Journal of Clinical Oncology. 26:51-58
The standard of care for first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) in patients who cannot tolerate platinum-based regimens has not been clarified. We aimed to develop a new treatment
Autor:
Barbara Burtness, Kevin J Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett G M Hughes, Ricard Mesía, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Ruey-Long Hong, René González Mendoza, Ananya Roy, Yayan Zhang, Burak Gumuscu, Jonathan D Cheng, Fan Jin, Danny Rischin, Guillermo Lerzo, Marcelo Tatangelo, Mirta Varela, Juan Jose Zarba, Michael Boyer, Hui Gan, Bo Gao, Brett Hughes, Girish Mallesara, Anne Taylor, Martin Burian, Carlos Henrique Barrios, Dalvaro Oliveira de Castro Junior, Gilberto Castro, Fabio Andre Franke, Gustavo Girotto, Iane Pinto Figueiredo Lima, Ulisses Ribaldo Nicolau, Gustavo Dix Junqueira Pinto, Lucas Santos, Ana-Paula Victorino, Neil Chua, Felix Couture, Richard Gregg, Aaron Hansen, John Hilton, Joy McCarthy, Denis Soulieres, Rodrigo Ascui, Pablo Gonzalez, Luis Villanueva, Marco Torregroza, Angela Zambrano, Petra Holeckova, Zdenek Kral, Bohuslav Melichar, Jana Prausova, Milan Vosmik, Maria Andersen, Niels Gyldenkerne, Hannes Jurgens, Kadri Putnik, Petri Reinikainen, Viktor Gruenwald, Simon Laban, Gerasimos Aravantinos, Ioannis Boukovinas, Vassilis Georgoulias, Dora Kwong, Yousuf Al-Farhat, Tibor Csoszi, Jozsef Erfan, Geza Horvai, Laszlo Landherr, Eva Remenar, Agnes Ruzsa, Judit Szota, Salem Billan, Iris Gluck, Orit Gutfeld, Aron Popovtzer, Marco Benasso, Simona Bui, Vittorio Ferrari, Lisa Licitra, Franco Nole, Takashi Fujii, Yasushi Fujimoto, Nobuhiro Hanai, Hiroki Hara, Koji Matsumoto, Kenji Mitsugi, Nobuya Monden, Masahiro Nakayama, Kenji Okami, Nobuhiko Oridate, Kiyoto Shiga, Yasushi Shimizu, Masashi Sugasawa, Masanobu Takahashi, Shunji Takahashi, Kaoru Tanaka, Tsutomu Ueda, Hironori Yamaguchi, Tomoko Yamazaki, Ryuji Yasumatsu, Tomoya Yokota, Tomokazu Yoshizaki, Iveta Kudaba, Zinaida Stara, Soon Keat Cheah, Jose Aguilar Ponce, Rene Gonzalez Mendoza, Carlos Hernandez Hernandez, Francisco Medina Soto, Jan Buter, Ann Hoeben, S. Oosting, Karijn Suijkerbuijk, Aase Bratland, Marianne Brydoey, Renzo Alvarez, Luis Mas, Priscilla Caguioa, John Querol, Eugenio Emmanuel Regala, Maria Belen Tamayo, Ellie May Villegas, Andrzej Kawecki, Andrey Karpenko, Arkadiy Klochikhin, Alexey Smolin, Oleg Zarubenkov, Boon Cher Goh, Graham Cohen, Johanna du Toit, Christa Jordaan, Gregory Landers, Paul Ruff, Waldemar Szpak, Neonyana Tabane, Irene Brana, Lara Iglesias Docampo, Javier Lavernia, Ricard Mesia, Edvard Abel, Valentina Muratidu, Niels Nielsen, Valerie Cristina, Sacha Rothschild, Hung-Ming Wang, Muh-Hwa Yang, Su-Peng Yeh, Chia-Jui Yen, Nopadol Soparattanapaisarn, Virote Sriuranpong, Sercan Aksoy, Irfan Cicin, Meltem Ekenel, Hakan Harputluoglu, Ozgur Ozyilkan, Kevin Harrington, Sanjiv Agarwala, Haythem Ali, Robert Alter, Daniel Anderson, Justine Bruce, Nicholas Campbell, Miguel Conde, John Deeken, William Edenfield, Lawrence Feldman, Elizabeth Gaughan, Basem Goueli, Balazs Halmos, Upendra Hegde, Brian Hunis, Robert Jotte, Anand Karnad, Saad Khan, Noel Laudi, Douglas Laux, Danko Martincic, Steven McCune, Dean McGaughey, Krzysztof Misiukiewicz, Deborah Mulford, Eric Nadler, Johannes Nunnink, James Ohr, Meaghan O'Malley, Brian Patson, Doru Paul, Elizabeta Popa, Steven Powell, Rebecca Redman, Vincent Rella, Chaio Rocha Lima, Abirami Sivapiragasam, Yungpo Su, Ammar Sukari, Stuart Wong, Emrullah Yilmaz, Jeffrey Yorio
Publikováno v:
The Lancet, 394(10212), 1915-1928. ELSEVIER SCIENCE INC
BACKGROUND: Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response.METHODS: KEYNOTE-048 was a randomised, phase 3 study of participants with u
Autor:
Takahiro Asakage, Kiyoaki Tsukahara, Makoto Arai, Takashi Fujii, Tomoko Yamazaki, Daiju Sakurai, Nobuya Monden, Tsutomu Ueda, Akihiro Homma, Naomi Kudo, Takayuki Yamada, Takeharu Ono, Shunji Takahashi, Koichi Omori, Tomoya Yokota, Masafumi Yoshida, Ryuji Yasumatsu, Moriyasu Yamauchi, Hitoshi Hirakawa, Yasushi Shimizu, Akihito Watanabe, Kenji Hanyu, Daisuke Sano, Issei Doi, Shin Kariya, Nobuhiro Hanai
Publikováno v:
International Journal of Clinical Oncology. 26:1005-1006
The article Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real‑world clinical practice: a multicentre retrospective clinical study, written by.
Autor:
Nobuhiro Hanai, Makoto Arai, Tomoko Yamazaki, Nobuya Monden, Naomi Kudo, Tsutomu Ueda, Shunji Takahashi, Koichi Omori, Takashi Fujii, Takayuki Yamada, Shin Kariya, Issei Doi, Kiyoaki Tsukahara, Masafumi Yoshida, Yasushi Shimizu, Kenji Hanyu, Akihiro Homma, Takahiro Asakage, Daisuke Sano, Ryuji Yasumatsu, Akihito Watanabe, Daiju Sakurai, Moriyasu Yamauchi, Tomoya Yokota, Takeharu Ono, Hitoshi Hirakawa
Publikováno v:
International Journal of Clinical Oncology
Background To fill the data gap between clinical trials and real-world settings, this study assessed the overall effectiveness and safety of nivolumab in patients with head and neck cancer (HNC) during Japanese real-world clinical practice. Methods T
Autor:
Susumu Okano, Akihiro Homma, Takenori Ogawa, Atsushi Motegi, Makoto Tahara, Shujiro Minami, Kenji Okami, Tomohiro Enokida, Takao Fujisawa, Jun Taguchi, Ayako Nakanome, Shogo Nomura, Yasushi Shimizu, Koji Ebisumoto, Akira Ohkoshi, Daisuke Maki, Yuri Ueda
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 5, Pp 1671-1682 (2020)
Cancer Medicine, Vol 9, Iss 5, Pp 1671-1682 (2020)
Background Induction chemotherapy (IC) in locally advanced squamous cell carcinoma of the head and neck (LA‐SCCHN) often compromises compliance with subsequent chemoradiotherapy (CRT), which negatively affects outcomes. Here, we assessed the combin
Autor:
Akihiro Homma, S. Zenda, Takeshi Kodaira, Takenori Ogawa, Hirofumi Fujii, Shigemichi Iwae, Nobuhiro Hanai, Koichiro Yonezawa, Tetsuro Onitsuka, Susumu Okano, Tomoya Yokota, Shunji Takahashi, Kazuto Matsuura, Yasushi Shimizu, Makoto Tahara, Tetsuo Akimoto, Naomi Kiyota, Ryuichi Hayashi, Takahiro Asakage, Nobuya Monden
Publikováno v:
Japanese journal of clinical oncology. 49(7)
A number of major modifications were made to the classification of head and neck carcinomas in the eighth edition of the American Joint Committee on Cancer, Cancer Staging Manual and Union for International Cancer Control TNM classification of Malign
Autor:
Yasushi Shimizu, Toshio Kubo, Chikashi Ishioka, Satoshi Miyake, Hideyuki Hayashi, Hisahiro Matsubara, Sadakatsu Ikeda, Hirotoshi Dosaka-Akita, Masayuki Kano, Yukiko Mori, Eri Ishibashi, Naoko Sueoka-Aragane, Hiroshi Nishihara, Akihiro Hirakawa, Kenta Takahashi, Ukihide Tateishi, Shinichi Toyooka, Manabu Muto, Yohei Harada, Hidekazu Shirota
Publikováno v:
Medicine
Supplemental Digital Content is available in the text
Introduction: Human epidermal growth factor receptor 2 (HER2) gene amplification and mutations have emerged as oncogenic drivers and therapeutic targets not limited to breast and gastric canc
Introduction: Human epidermal growth factor receptor 2 (HER2) gene amplification and mutations have emerged as oncogenic drivers and therapeutic targets not limited to breast and gastric canc